Aclaris Operating Income from 2010 to 2024

ACRS Stock

USD 4.32 0.36 9.09%

Aclaris Therapeutics Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income will likely drop to about -102.2 M in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Aclaris Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2013-12-31

Previous Quarter

-12.6 M

Current Value

-10.5 M

Quarterly Volatility

11.6 M

Yuan Drop

Covid

Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 819.9 K, Interest Expense of 3.2 M or Selling General Administrative of 21.3 M, as well as many indicators such as Price To Sales Ratio of 2.23, Dividend Yield of 0.0 or PTB Ratio of 0.67. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.

Check out the analysis of Aclaris Therapeutics Correlation against competitors.

For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

Latest Aclaris Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Aclaris Therapeutics over the last few years. Operating Income is the amount of profit realized from Aclaris Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Aclaris Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Aclaris Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aclaris Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Aclaris Operating Income Regression Statistics

	Arithmetic Mean	(54,581,457)
	Coefficient Of Variation	(82.29)
	Mean Deviation	38,259,287
	Median	(50,912,000)
	Standard Deviation	44,916,377
	Sample Variance	2017.5T
	Range	130.2M
	R-Value	(0.81)
	Mean Square Error	761.9T
	R-Squared	0.65
	Significance	0.0003
	Slope	(8,093,336)
	Total Sum of Squares	28244.7T

Aclaris Operating Income History

	2024	-102.2 M
	2023	-97.4 M
	2022	-85.2 M
	2021	-65.4 M
	2020	-50.9 M
	2019	-111.1 M
	2018	-135.4 M

Other Fundumenentals of Aclaris Therapeutics

Non Operating Income Net Other

Aclaris Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Net Receivables	Capital Surpluse	Common Stock	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Long Term Debt Total	Current Deferred Revenue
Total Assets		0.99	-0.48	-0.62	0.86	0.94	0.51	0.97	0.28	0.97	0.59	0.49	0.52	0.73	0.82	0.02	-0.19	-0.01	0.5	-0.33	0.46
Total Stockholder Equity	0.99		-0.53	-0.56	0.79	0.95	0.36	0.98	0.26	0.98	0.51	0.5	0.47	0.67	0.81	0.04	-0.18	0.01	0.42	-0.27	0.42
Net Debt	-0.48	-0.53		0.13	-0.34	-0.58	0.07	-0.52	-0.26	-0.48	-0.05	-0.14	-0.03	-0.21	-0.46	0.04	0.03	0.02	0.0	0.02	-0.03
Retained Earnings	-0.62	-0.56	0.13		-0.73	-0.52	-0.62	-0.57	-0.42	-0.63	-0.8	-0.64	-0.14	-0.94	-0.78	0.61	0.58	0.55	-0.72	0.87	-0.69
Accounts Payable	0.86	0.79	-0.34	-0.73		0.7	0.72	0.77	0.61	0.77	0.9	0.3	0.68	0.8	0.84	-0.29	-0.19	-0.36	0.63	-0.57	0.4
Short Term Investments	0.94	0.95	-0.58	-0.52	0.7		0.35	0.98	0.18	0.91	0.38	0.44	0.29	0.63	0.73	0.08	-0.11	0.15	0.49	-0.27	0.4
Total Liab	0.51	0.36	0.07	-0.62	0.72	0.35		0.39	0.19	0.36	0.71	0.12	0.53	0.67	0.44	-0.12	-0.14	-0.14	0.69	-0.44	0.45
Total Current Assets	0.97	0.98	-0.52	-0.57	0.77	0.98	0.39		0.25	0.95	0.48	0.48	0.38	0.67	0.8	0.03	-0.15	0.07	0.5	-0.32	0.43
Property Plant Equipment	0.28	0.26	-0.26	-0.42	0.61	0.18	0.19	0.25		0.24	0.7	-0.01	0.28	0.36	0.56	-0.63	-0.07	-0.64	0.29	-0.66	-0.02
Net Tangible Assets	0.97	0.98	-0.48	-0.63	0.77	0.91	0.36	0.95	0.24		0.53	0.62	0.39	0.75	0.81	-0.01	-0.28	-0.06	0.4	-0.34	0.55
Deferred Long Term Liab	0.59	0.51	-0.05	-0.8	0.9	0.38	0.71	0.48	0.7	0.53		0.22	0.58	0.8	0.75	-0.58	-0.22	-0.64	0.7	-0.77	0.39
Long Term Investments	0.49	0.5	-0.14	-0.64	0.3	0.44	0.12	0.48	-0.01	0.62	0.22		-0.14	0.57	0.52	-0.17	-0.81	-0.21	0.09	-0.4	0.6
Net Receivables	0.52	0.47	-0.03	-0.14	0.68	0.29	0.53	0.38	0.28	0.39	0.58	-0.14		0.23	0.41	0.09	0.1	-0.15	0.23	0.05	-0.09
Capital Surpluse	0.73	0.67	-0.21	-0.94	0.8	0.63	0.67	0.67	0.36	0.75	0.8	0.57	0.23		0.79	-0.44	-0.37	-0.41	0.74	-0.78	0.77
Common Stock	0.82	0.81	-0.46	-0.78	0.84	0.73	0.44	0.8	0.56	0.81	0.75	0.52	0.41	0.79		-0.49	-0.3	-0.49	0.6	-0.65	0.37
Net Invested Capital	0.02	0.04	0.04	0.61	-0.29	0.08	-0.12	0.03	-0.63	-0.01	-0.58	-0.17	0.09	-0.44	-0.49		0.32	0.92	-0.47	0.83	-0.09
Short Long Term Debt	-0.19	-0.18	0.03	0.58	-0.19	-0.11	-0.14	-0.15	-0.07	-0.28	-0.22	-0.81	0.1	-0.37	-0.3	0.32		0.38	0.05	0.38	-0.45
Net Working Capital	-0.01	0.01	0.02	0.55	-0.36	0.15	-0.14	0.07	-0.64	-0.06	-0.64	-0.21	-0.15	-0.41	-0.49	0.92	0.38		-0.3	0.7	-0.05
Short Term Debt	0.5	0.42	0.0	-0.72	0.63	0.49	0.69	0.5	0.29	0.4	0.7	0.09	0.23	0.74	0.6	-0.47	0.05	-0.3		-0.7	0.33
Long Term Debt Total	-0.33	-0.27	0.02	0.87	-0.57	-0.27	-0.44	-0.32	-0.66	-0.34	-0.77	-0.4	0.05	-0.78	-0.65	0.83	0.38	0.7	-0.7		-0.48
Current Deferred Revenue	0.46	0.42	-0.03	-0.69	0.4	0.4	0.45	0.43	-0.02	0.55	0.39	0.6	-0.09	0.77	0.37	-0.09	-0.45	-0.05	0.33	-0.48

Click cells to compare fundamentals

About Aclaris Therapeutics Financial Statements

Aclaris Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-97.4 M	-102.2 M
Non Operating Income Net Other	2.7 M	2.8 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aclaris Operating Income from 2010 to 2024

Latest Aclaris Therapeutics' Operating Income Growth Pattern

Aclaris Operating Income Regression Statistics

Aclaris Operating Income History

Other Fundumenentals of Aclaris Therapeutics

Aclaris Therapeutics Operating Income component correlations

About Aclaris Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Aclaris Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY